CPB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CPB is not a good buy right now for a Beginner with a long-term focus and $50,000-$100,000 to invest. The stock is near resistance, fundamentals are weakening, and analysts have recently turned more cautious with multiple target cuts. While there are some supportive hedge fund flows and the dividend remains attractive, the overall setup does not justify an immediate buy for an impatient long-term investor. I would not buy it now.
CPB is trading at 21.2017, just below the key pivot at 20.743 and very near resistance at R1 21.293, with R2 at 21.633. MACD histogram is positive and expanding at 0.165, which is a short-term bullish sign, but RSI_6 at 69.025 shows the stock is approaching overbought territory. Moving averages are converging, suggesting a lack of strong trend conviction. The near-term pattern analysis also points to downside pressure, with a 60% chance of -0.64% next day, -3.26% next week, and -6.28% next month.
["Hedge funds are buying aggressively, with reported buying up 10801.13% over the last quarter.", "News flow includes Campbell's acquisition of a 49% stake in La Regina to support Rao's Homemade growth.", "Rao's Homemade has surpassed $1 billion in net sales, becoming a meaningful growth brand in the portfolio.", "The company continues to offer an attractive dividend yield, which remains a draw for income-oriented investors.", "Options positioning is not strongly bearish, with put-call ratios favoring calls on open interest."]
["Revenue fell 4.51% YoY in the latest quarter, while net income fell 16.18% and EPS fell 17.24%.", "Gross margin declined 7.42% YoY to 27.93, showing ongoing profitability pressure.", "Analyst sentiment has deteriorated, with multiple price target cuts and downgrades in recent weeks.", "Bernstein downgraded the stock to Market Perform and cut its target to $21, saying the upgrade thesis has not played out.", "The technical setup is weak near resistance, and near-term modeled price action points downward."]
Latest quarter shown is 2026/Q2. Revenue was 2.564 billion, down 4.51% YoY. Net income was 145 million, down 16.18% YoY. EPS was 0.48, down 17.24% YoY. Gross margin fell to 27.93%, down 7.42% YoY. Overall, the quarter showed declining growth and margin compression rather than a recovery trend.
Analyst sentiment is clearly cautious to bearish. Bernstein downgraded CPB to Market Perform with a $21 target after its earlier bullish thesis failed. Morgan Stanley, Stifel, Barclays, BNP Paribas, Wells Fargo, TD Cowen, Deutsche Bank, and UBS all lowered targets or kept Hold/Underweight/Sell-type ratings. The Wall Street pros and cons view is mostly negative: pros include a defensive consumer staples profile and dividend appeal, while cons center on weak volume growth, brand underperformance, cost inflation, margin pressure, and limited near-term recovery potential.
